With an annual estimated overall cost of $3 billion to $5 billion in the U.S., SSIs are associated with a nearly 10-day increased length of stay and an increase of $20,000 in the cost of hospitalization per admission.
Furthermore, SSIs are the most costly of all hospital-acquired infections. Although most patients recover from an SSI without any long-term consequences, they are at a two- to 11-fold increased risk of mortality. SSIs account for 20 percent of all infections that occur in the hospital setting. Research indicates that SSIs are the most common type of hospital-acquired infection. Surgery also presents a significant risk to patients, and together, the operating room should be on the infection preventionist's radar for healthcare-associated infection (HAI) mitigation and elimination. doi:10.1001/ hospital's surgical services department represents one of the most sizable challenges to infection prevention and control. Financial Impact of Surgical Site Infections on Hospitals: The Hospital Management Perspective. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.Ĥ Ban KA, Minei JP, Laronga C, et al. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. is a Canadian headquartered company innovating in the field of photodisinfection therapies. When illuminated with a specific wavelength of light, the photosensitizer is activated, causing an oxidative burst that is lethal to all types of pathogens. Ondine’s nasal photodisinfection is a patented technology which uses a proprietary, non-antibiotic photosensitizer to destroy pathogens.
4 A patient who develops an SSI will spend an average of five additional days in hospital, 5 significantly increasing their recovery time and costs.Īll patients in the study were treated with a single, 5-minute treatment of Ondine’s nasal photodisinfection, which eliminates infection-causing bacteria, viruses and fungi in the nose. SSIs are responsible for most hospital readmissions following surgery and are a significant cause of post-surgical morbidity and mortality, increasing the risk of mortality by 2- to 11-fold. aureus, including MRSA, is a major contributor to SSIs, and nasal decolonization has proven to be highly effective in preventing SSIs by eradicating S. The nose is a well-known reservoir of infection-causing pathogens. Of the 313 patients who underwent the treatment prior to surgery, 21% were found to have S. Moreover, the study results showed that Ondine’s nasal photodisinfection eliminated or significantly reduced Staphylococcus aureus, including MRSA, in 88% of carriers immediately after treatment. The Centers for Disease Control and Prevention (CDC) estimates that over 110,000 SSIs occur in the US each year, costing the healthcare system approximately $3.3 billion. The results indicate that patients who underwent Ondine’s nasal photodisinfection prior to surgery experienced 66% fewer surgical site infections (SSIs) than the US national average.
#SSIS 029 TRIAL#
(LON: OBI) presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33 rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark. VANCOUVER, Canada-( BUSINESS WIRE)-Ondine Biomedical Inc.
0 kommentar(er)
